Several randomized controlled trials (RCTs) that focused on Osimertinib used for advanced NSCLC patients have been released; however, the clinical benefits of Osimertinib in advanced NSCLC patients with different EGFR mutation types as well as other clinical characteristics remain unresolved. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.